Welcome
to Teglutik®

Teglutik® is the first oral liquid suspension formulation of riluzole, the only licensed treatment for patients with amyotrophic lateral sclerosis (ALS), the most common type of motor neuron disease (MND).

This site provides information on Teglutik® and ALS for UK-based healthcare professionals and patients. Please select from the buttons below to tailor the content to your needs:

I am a UK healthcare professional
I am not a healthcare professional

For additional information about MND you can visit the Motor Neurone Disease Association website. The Motor Neurone Disease Association is the only national charity in England, Wales and Northern Ireland focused on MND care, research and campaigning

http://www.mndassociation.org/